



Alan Kelly, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

30th November 2021

PQ: 55728/21

To ask the Minister for Health when the drug Epidiolex will be available on the drug reimbursement scheme; and if he will make a statement on the matter. -Alan Kelly

Dear Deputy Kelly,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 55728/21), which you submitted to the Minister for Health for response.

‘Effective December 1st 2021, the HSE has approved reimbursement of Cannabidiol (Epidyolex®) 100 mg/ml oral solution via the High Tech Drug Arrangements for the following indications:

- use as adjunctive therapy of seizures associated with Lennox-Gastaut Syndrome (LGS) in conjunction with Clobazam, for patients 2 years of age and older,
- use as adjunctive therapy of seizures associated with Dravet Syndrome (DS) in conjunction with Clobazam, for patients 2 years of age and older, and
- use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.

Approved prescribers will be required to provide confirmation that Cannabidiol (Epidyolex®) 100 mg/ml oral solution is being prescribed in accordance with the licensed indications and in line with the terms of reimbursement approval given by the HSE.’

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Suzanne Doyle'.

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service